Skip to main content
OpenTrials
Completed

NCT Number: NCT04394143

Effect of AD128 to Treat Obstructive Sleep Apnea

This study evaluates the combination of two drugs (AD128), to treat obstructive sleep apnea (OSA) severity. After a baseline evaluation and during 7 days, half of the participants will randomly receive this drug combination (AD128) and the other will receive a placebo, i.e. a drug without pharmaceutical effect. Neither the participants, nor the investigators will know in which arm participants are until the end of the study. After one week of trial, an evaluation will be perform and will be follow by one week without any treatment. During the third and last week of trial, there will be a crossover of the groups, i.e. the participants of the first group who took the two drugs (AD128) during the first week will take a placebo and those who took the placebo will take the drugs combination.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Sleep Apnea, Obstructive Apnea Dyssomnias Nervous System Diseases Pathological Conditions, Signs and Symptoms Respiration Disorders Respiratory Tract Diseases Signs and Symptoms Sleep Apnea Syndromes Sleep Disorders, Intrinsic Sleep Wake Disorders Sleepiness

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Centre Hospitalier Universitaire Vaudois

Lausanne, 1011, Switzerland

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults (>18 years and ≤ 65 years)
  • New or previous diagnosis of OSA with an AHI > 15/h on a polygraphic or polysomnographic recording (Participants already treated with continuous positive airway pressure (CPAP) or mandibular advancement device can be included but a 7-days wash-out period is required before the beginning of the protocol and CPAP usage will not be possible during the whole protocol duration),
  • Informed Consent as documented by signature (Appendix Informed Consent Form)

Exclusion criteria

  • History of seizures,
  • History of glaucoma,
  • History of benign prostatic hyperplasia, organic miction disorder or urinary retention,
  • Gastrointestinal disease (e.g. stenosis, occlusion, ulcerative colitis, toxic megacolon, hiatal hernia…)
  • Cardiac arrhythmia,
  • History of bipolar disorder,
  • Use of respiratory stimulants or depressants,
  • Use of Hypnotics,
  • Use of Central nervous system stimulants,
  • Use of Monoamine oxidase inhibitors (MAOIs) antidepressant,
  • Major depressive disorder,
  • Central sleep apnea representing more than 10% of all respiratory events
  • Contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to class of drugs or the investigational product,
  • Pregnant or breast feeding female participants or participants who intend to become pregnant during the study (However, there is no contraindication to contraception),
  • Other clinically significant concomitant disease states (renal failure, hepatic dysfunction, severe cardiovascular or respiratory disease, myasthenia gravis, cerebral sclerosis),
  • Known or suspected non-compliance, drug or alcohol abuse,
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant,
  • Participation in another study with investigational drug within the 30 days preceding and during the present study
  • Use or morphinic and derivatives which may influence sleep,
  • Refusal to be informed in case of incidental findings.

Treatment and study plan

AD128

Drug

Oral administration of two capsules before sleep for 7 days.

Mannitol

Drug

Oral administration of two capsules before sleep for 7 days.

Other names: Placebo

Primary outcomes

  1. Apnea-hypopnea index (AHI)

    Time frame: Day 7 and 21

    Change from baseline AHI (events/h) measured via polysomnography between the week of investigational treatment (AD128) and the week of placebo treatment.

Secondary outcomes

  1. Oxygen desaturation index (ODI)

    Time frame: Day 7 and 21

    Change from baseline ODI (events/h) measured via polysomnography between the week of investigational treatment (AD128) and the week of placebo treatment.

  2. Oxygen desaturation index (ODI) in REM and NREM

    Time frame: Day 7 and 21

    Change from baseline ODI (events/h) measured via polysomnography during rapid eye movement (REM) and non rapid eye movement (NREM) sleep between the week of investigational treatment (AD128) and the week of placebo treatment.

  3. Hypoxic load

    Time frame: Day 7 and 21

    Change from baseline hypoxic load (area under the curve of 3% oxygen desaturation related to apnea-hypopnea events) measured via polysomnography between the week of investigational treatment (AD128) and the week of placebo treatment.

  4. Hypoxic load in REM and NREM

    Time frame: Day 7 and 21

    Change from baseline hypoxic load (area under the curve of 3% oxygen desaturation related to apnea-hypopnea events) measured via polysomnography during rapid eye movement (REM) and non rapid eye movement (NREM) sleep between the week of investigational treatment (AD128) and the week of placebo treatment.

  5. Arousal index

    Time frame: Day 7 and 21

    Change from baseline arousal index (events/h) measured via polysomnography between the week of investigational treatment (AD128) and the week of placebo treatment.

  6. Arousal index in REM and NREM

    Time frame: Day 7 and 21

    Change from baseline arousal index (events/h) measured via polysomnography during rapid eye movement (REM) and non rapid eye movement (NREM) sleep between the week of investigational treatment (AD128) and the week of placebo treatment.

  7. Pulse wave amplitude (PWA) drops

    Time frame: Day 7 and 21

    Change from baseline PWA drops (events/h) measured via polysomnography between the week of investigational treatment (AD128) and the week of placebo treatment.

  8. Pulse wave amplitude (PWA) drops in REM and NREM

    Time frame: Day 7 and 21

    Change from baseline PWA drops (events/h) measured via polysomnography during rapid eye movement (REM) and non rapid eye movement (NREM) sleep between the week of investigational treatment (AD128) and the week of placebo treatment.

  9. Apnea-hypopnea index (AHI) in REM and NREM

    Time frame: Day 7 and 21

    Change from baseline AHI (events/h) measured via polysomnography during rapid eye movement (REM) and non rapid eye movement (NREM) sleep between the week of investigational treatment (AD128) and the week of placebo treatment.

  10. Percentage of REM sleep

    Time frame: Day 7 and 21

    Change from baseline REM sleep (% of total sleep time) measured via polysomnography between the week of investigational treatment (AD128) and the week of placebo treatment.

  11. Percentage of N1

    Time frame: Day 7 and 21

    Change from baseline sleep stage 1 (N1: % of total sleep time) measured via polysomnography between the week of investigational treatment (AD128) and the week of placebo treatment.

  12. Percentage of N2

    Time frame: Day 7 and 21

    Change from baseline sleep stage 2 (N2: % of total sleep time) measured via polysomnography between the week of investigational treatment (AD128) and the week of placebo treatment.

  13. Percentage of N3

    Time frame: Day 7 and 21

    Change from baseline sleep stage 3 (N3: % of total sleep time) measured via polysomnography between the week of investigational treatment (AD128) and the week of placebo treatment.

  14. Percentage of alpha wave

    Time frame: Day 7 and 21

    Change from baseline alpha wave frequency (8-13 Hz - % of total sleep time) measured via polysomnography in REM and NREM between the week of investigational treatment (AD128) and the week of placebo treatment.

  15. Percentage of beta wave

    Time frame: Day 7 and 21

    Change from baseline beta wave frequency (13-30 Hz - % of total sleep time) measured via polysomnography in REM and NREM between the week of investigational treatment (AD-128) and the week of placebo treatment.

  16. Percentage of gamma wave

    Time frame: Day 7 and 21

    Change from baseline gamma wave frequency (30-100 Hz - % of total sleep time) measured via polysomnography in REM and NREM between the week of investigational treatment (AD128) and the week of placebo treatment.

  17. Percentage of theta wave

    Time frame: Day 7 and 21

    Change from baseline theta wave frequency (4-8 Hz - % of total sleep time) measured via polysomnography in REM and NREM between the week of investigational treatment (AD128) and the week of placebo treatment.

  18. Percentage of delta wave

    Time frame: Day 7 and 21

    Change from baseline delta wave frequency (1-4 Hz - % of total sleep time) measured via polysomnography in REM and NREM between the week of investigational treatment (AD128) and the week of placebo treatment.

  19. Reaction time PVT

    Time frame: Day 7 and 21

    Change from baseline reaction time (in ms) during Psychomotor Vigilance Task (PVT). During 10 min, subjects were instructed to press a button as quickly as possible when a red millisecond-counter appeared on a small screen (PVT-192, Ambulatory Monitoring Inc.).

  20. Lapse PVT

    Time frame: Day 7 and 21

    Change from baseline lapse time (in ms) during Psychomotor Vigilance Task (PVT) and defined as reaction time > 500 ms). During 10 min, subjects were instructed to press a button as quickly as possible when a red millisecond-counter appeared on a small screen (PVT-192, Ambulatory Monitoring Inc.).

  21. Chronic Excessive daytime sleepiness (EDS)

    Time frame: Day 7 and 21

    Change from baseline Epworth Sleepiness Scale (ESS) score between the week of investigational treatment (AD128) and the week of placebo treatment.

    The ESS is a 8-item questionnaire. ESS score can range from 0 to 24. The higher the ESS score, the higher daytime sleepiness.

  22. Acute Excessive daytime sleepiness (EDS)

    Time frame: Day 7 and 21

    Change from baseline Stanford Sleepiness Scale (SSS) score between the week of investigational treatment (AD128) and the week of placebo treatment.

    Consisting of only one item, the scale requires respondents to select one of seven statements best representing their level of perceived sleepiness. The scale range from 1 to 7. Higher score indicates greater sleepiness.

  23. Sleep quality

    Time frame: Day 7 and 21

    Change from baseline visual analogic scale (VAS) sleep quality score between the week of investigational treatment (AD128) and the week of placebo treatment. Score ranges from 0 to 10. Higher score indicates better sleep quality.

  24. Fatigue

    Time frame: Day 7 and 21

    Change from baseline Pichot scale score between the week of investigational treatment (AD128) and the week of placebo treatment.

    The Pichot scale is a 8-items auto-questionnaire to assess excessive fatigue. Score varies between 0 and 32, a score > 22 indicates excessive fatigue.

  25. Systolic and diastolic blood pressure

    Time frame: Day 7 and 21

    Change from baseline office systolic and diastolic blood pressure (BP in mm Hg) between the week of investigational treatment (AD128) and the week of placebo treatment.

    The Pichot scale is a 8-items auto-questionnaire to assess excessive fatigue. Score varies between 0 and 32, a score > 22 indicates excessive fatigue.

Sponsors and collaborators

Lead sponsor

Raphael Heinzer

Other

Collaborators

  • Apnimed

Registry information

Official study title

Effect of AD128 on Obstructive Sleep Apnea Severity: a Randomized, Placebo-controlled, Double-blind, Cross-over Study

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
May 19, 2020
Registry last updated
Aug 6, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.